{
  "questions": [
    {
      "body": "Which enhancers are characterized as latent?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23332752"
      ], 
      "type": "summary", 
      "id": "5ca60a77ecadf2e73f00004d", 
      "snippets": [
        {
          "offsetInBeginSection": 368, 
          "offsetInEndSection": 606, 
          "text": "Here, we describe latent enhancers, defined as regions of the genome that in terminally differentiated cells are unbound by TFs and lack the histone marks characteristic of enhancers but acquire these features in response to stimulation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332752", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the difference between COG133 and COG112?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16740622"
      ], 
      "type": "summary", 
      "id": "5c88b8a275a4a5d21900000b", 
      "snippets": [
        {
          "offsetInBeginSection": 728, 
          "offsetInEndSection": 1017, 
          "text": "Most notably, fusion of COG133 to a protein transduction domain creates COG112, a modified apoE-mimetic peptide with significantly enhanced anti-inflammatory bioactivities in vitro, and improved therapeutic effects on EAE in vivo, which renders a nearly full remission from the disability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16740622", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15734119", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16617304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9674897"
      ], 
      "type": "yesno", 
      "id": "5c97a08becadf2e73f000029", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 117, 
          "text": "The deletion of chromosome 22q11.2 is involved in the majority of DiGeorge or velo-cardiofacial syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15734119", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 315, 
          "offsetInEndSection": 451, 
          "text": "deletions of chromosome 7q11.23 (Williams syndrome), 15q11-q13 (Angelman syndrome, Prader-Willi syndrome) and 22q11 (Di George syndrome)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16617304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 201, 
          "text": "Submicroscopic deletions of chromosome 22q11 have been reported in a multiple anomaly syndrome variously labelled as velocardiofacial syndrome, conotruncal anomaly face syndrome, and Di George syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9674897", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the protein Asporin related to disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28152543", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27705916", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27409832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25689697"
      ], 
      "type": "yesno", 
      "id": "5c8ab614d558e5f23200000d", 
      "snippets": [
        {
          "offsetInBeginSection": 307, 
          "offsetInEndSection": 388, 
          "text": "Accumulating evidence demonstrates the involvement of asporin in OA pathogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27409832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Asporin has been implicated as an oncogene in various types of human cancers; ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27705916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1264, 
          "offsetInEndSection": 1425, 
          "text": " These results suggested that asporin promoted the tumor growth and metastasis of CRC, and it could be a potential therapeutic target for CRC patients in future.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27705916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1975, 
          "offsetInEndSection": 2118, 
          "text": "Our results suggest that ASPN is a stromally expressed biomarker that correlates with disease progression, and is observed in reactive stroma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28152543", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can TAD disruption lead to disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29990539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30241613", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26862051"
      ], 
      "type": "yesno", 
      "id": "5ca61176ecadf2e73f00004e", 
      "snippets": [
        {
          "offsetInBeginSection": 695, 
          "offsetInEndSection": 954, 
          "text": "its perturbation will lead to human disease, highlighting the accumulating evidence that links the diverse 3D genome architecture components to a multitude of human diseases and the emerging mechanisms by which 3D genome derangement causes disease phenotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29990539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "TAD boundaries are insulators of genomic neighborhoods. In this issue, Sun et\u00a0al. show that disease-associated tandem repeats are located to TAD boundaries and affect their insulation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30241613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 552, 
          "offsetInEndSection": 773, 
          "text": "Recent studies of TAD boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter-enhancer interactions in the affected TADs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 775, 
          "offsetInEndSection": 941, 
          "text": "Similar boundary disruptions in certain cancers can result in oncogene overexpression, and CTCF binding sites at boundaries appear to be hyper-mutated across cancers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 546, 
          "text": "the disruption of these structures by genomic rearrangements can result in gene misexpression and disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26862051", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is L-4F an apoE mimetic peptide?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29245934"
      ], 
      "type": "yesno", 
      "id": "5c8908a475a4a5d21900000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29245934", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 337, 
          "text": "L-4F, an Apolipoprotein A-I (ApoA-I) mimetic peptide, is engineered to mimic the anti-inflammatory and anti-oxidative functionalities of ApoA-I.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29245934", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29398602", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30217516"
      ], 
      "type": "yesno", 
      "id": "5c98ac7fecadf2e73f00002b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 441, 
          "text": "The genus Anaplasma belonging to the Anaplasmataceae family (order Rickettsiales) comprises obligate intracellular Gram-negative bacteria of veterinary and public health importance. Six species and five types of strains genetically related are currently assigned to the genus Anaplasma including Anaplasma marginale, A. centrale, A. bovis, A. phagocytophilum, A. ovis and A. platys as classified species, and \"A. capra\", A. odocolei sp. nov.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29398602", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Human granulocytic anaplasmosis (HGA), an increasingly recognized febrile tick-borne illness, is caused by a gram-negative obligate intracellular bacterium Anaplasma phagocytophilum", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30217516", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which cells secrete lactotransferrin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24561791"
      ], 
      "type": "list", 
      "id": "5c8c095e0101eac870000002", 
      "snippets": [
        {
          "offsetInBeginSection": 1243, 
          "offsetInEndSection": 1393, 
          "text": "We conclude that lactotransferrin represents a late stage differentiation marker of neutrophils, macrophages and distinct subtypes of dendritic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561791", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which plant does oleuropein originate from?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29099642"
      ], 
      "type": "factoid", 
      "id": "5c890ad575a4a5d21900000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Oleuropein Is Responsible for the Major Anti-Inflammatory Effects of Olive Leaf Extract.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099642", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 745, 
          "offsetInEndSection": 854, 
          "text": "Oleuropein is the only OLE component that has shown anti-inflammatory effects at a concentration of 20\u2009\u03bcg/mL.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099642", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1015, 
          "offsetInEndSection": 1242, 
          "text": "Downregulation of TNF\u03b1 secretion in PMNCs culture in response to OLE treatment indicates that this polyphenol-rich extract has an anti-inflammatory effect, and oleuropein is the major OLE component responsible for this effect. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099642", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29059618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29486600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29554826"
      ], 
      "type": "factoid", 
      "id": "5ca0bf00ecadf2e73f000045", 
      "snippets": [
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 398, 
          "text": "Since IL-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting IL-5/IL-5R\u03b1 have been developed and/or marketed, including Mepolizumab, Reslizumab, and Benralizumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 14, 
          "offsetInEndSection": 383, 
          "text": "Reslizumab, a humanized mAb against IL-5, reduces the number of eosinophils in the blood and lungs. Based on efficacy and safety data from pivotal RCTs, reslizumab had been approved for use as an add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults who have a history of exacerbations despite receiving their current asthma medicines. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29486600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 57, 
          "text": "Reslizumab in the treatment of severe eosinophilic asthma", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29554826", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the function of the protein Magt1?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29581357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30385806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29051561"
      ], 
      "type": "factoid", 
      "id": "5c92869aecadf2e73f000015", 
      "snippets": [
        {
          "offsetInBeginSection": 162, 
          "offsetInEndSection": 193, 
          "text": "magnesium transporter 1 (MAGT1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29581357", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 217, 
          "offsetInEndSection": 244, 
          "text": "magnesium transporter MagT1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "The magnesium transporter 1 (MAGT1) is a critical regulator of basal intracellular free magnesium ([Mg2+]i) levels. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29051561", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can oleuropein aglycone interfere with amyloid aggregation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29571746"
      ], 
      "type": "yesno", 
      "id": "5c890c3375a4a5d21900000e", 
      "snippets": [
        {
          "offsetInBeginSection": 285, 
          "offsetInEndSection": 684, 
          "text": "Oleuropein, a phenolic secoiroid glycoside, is the main polyphenol in the olive oil. It has been reported that the aglycone form of Oleuropein (OleA) interferes in vitro and in vivo with amyloid aggregation of a number of proteins/peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic oligomers and displaying protection against cognitive deterioration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571746", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is subdural empyema a complication of sinusitis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29404826", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29682134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30014307"
      ], 
      "type": "yesno", 
      "id": "5ca0c81eecadf2e73f000047", 
      "snippets": [
        {
          "offsetInBeginSection": 19, 
          "offsetInEndSection": 180, 
          "text": "Acute and chronic sinusitis can give rise to a wide array of intracranial and orbital complications. These complications include brain abscess, subdural empyema,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404826", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 170, 
          "offsetInEndSection": 323, 
          "text": " A computed tomography scan showed bilateral paranasal sinus disease, and magnetic resonance imaging showed a right frontal abscess and subdural empyema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Frontal sinusitis complicated by a brain abscess and subdural empyema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 292, 
          "text": "In older children, sinusitis and otitis media are usually the source for subdural empyem", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30014307", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the transcriptional co-activator p300?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30323286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23211718"
      ], 
      "type": "factoid", 
      "id": "5c990241ecadf2e73f00002d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "The transcriptional co-activator p300 is a histone acetyltransferase (HAT) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323286", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "p300, a transcriptional co-activator with histone acetyl transferase (HAT) activity, plays an essential role in the pathogenesis of cardiomyocyte hypertrophy in response to multiple pro-hypertrophic stimuli including hyperglycemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23211718", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is another name for the plant Sideritis scardica?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22274814"
      ], 
      "type": "factoid", 
      "id": "5c890e6d75a4a5d21900000f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 221, 
          "text": "Sideritis scardica Griseb. (ironwort, mountain tea), an endemic plant of the Balkan Peninsula, has been used in traditional medicine in the treatment of gastrointestinal complaints, inflammation, and rheumatic disorders. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274814", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How are gas vesicle proteins used in imaging?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28956265", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29483636"
      ], 
      "type": "summary", 
      "id": "5ca9f5e4ecadf2e73f000052", 
      "snippets": [
        {
          "offsetInBeginSection": 217, 
          "offsetInEndSection": 466, 
          "text": "Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28956265", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 402, 
          "text": "Here, we show that gas vesicles (GVs), a unique class of gas-filled protein nanostructures with differential magnetic susceptibility relative to water, can produce robust contrast in magnetic resonance imaging (MRI) at sub-nanomolar concentrations, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29483636", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "From where is gamabufotalin (GBT) isolated?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30111043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28631214", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26894970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25175164"
      ], 
      "type": "factoid", 
      "id": "5c9904eaecadf2e73f00002e", 
      "snippets": [
        {
          "offsetInBeginSection": 1219, 
          "offsetInEndSection": 1610, 
          "text": "RCFs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. The characteristic chromatogram and QAMS established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in Chinese Pharmacopoeia ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30111043", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 249, 
          "text": "We identified three bufadienolides-the steroid-like compounds arenobufagin, gamabufotalin, and telocinobufagin-from the boreal toad,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28631214", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 165, 
          "offsetInEndSection": 235, 
          "text": "In the current study, gamabufotalin (GBT) was isolated from toad venom", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 55, 
          "text": "Gamabufotalin, a bufadienolide compound from toad venom", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25175164", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What are super-enhancers", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29754476"
      ], 
      "type": "summary", 
      "id": "5c895e5ef9c2ba6b28000002", 
      "snippets": [
        {
          "offsetInBeginSection": 355, 
          "offsetInEndSection": 719, 
          "text": "Super-enhancers are large clusters of enhancers covering the long region of regulatory DNA and are densely occupied by transcription factors, active histone marks, and co-activators. Accumulating evidence points to the critical role that super-enhancers play in cell type-specific development and differentiation, as well as in the development of various diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29754476", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Apelin usually decreased in diabetes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29229313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25914650"
      ], 
      "type": "yesno", 
      "id": "5caa0806ecadf2e73f000057", 
      "snippets": [
        {
          "offsetInBeginSection": 558, 
          "offsetInEndSection": 816, 
          "text": "Apelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion. Moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25914650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 630, 
          "offsetInEndSection": 791, 
          "text": "Upregulated expression of resistin, vaspin, apelin and TNF-\u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29229313", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a mitosome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30265292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28372543", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21984067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20382757"
      ], 
      "type": "factoid", 
      "id": "5c9a6693ecadf2e73f000031", 
      "snippets": [
        {
          "offsetInBeginSection": 93, 
          "offsetInEndSection": 179, 
          "text": "Mitosomes are the simplest and the least well-studied type of anaerobic mitochondria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30265292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 492, 
          "text": "The mitosomes have abandoned typical mitochondrial traits such as the mitochondrial genome and aerobic respiration and their single role known to date is the formation of iron-sulfur clusters", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28372543", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 59, 
          "offsetInEndSection": 138, 
          "text": "a mitosome, a relict mitochondrion with a greatly reduced metabolic capability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21984067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 226, 
          "offsetInEndSection": 421, 
          "text": "he highly divergent mitochondrion-related organelle, the mitosome, in the anaerobic/microaerophilic protozoan parasite Entamoeba histolytica based on the potential mitochondrion-targeting signal.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20382757", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the price of KYMRIAH treatment in 2019?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29764166"
      ], 
      "type": "factoid", 
      "id": "5c897082d558e5f232000004", 
      "snippets": [
        {
          "offsetInBeginSection": 284, 
          "offsetInEndSection": 646, 
          "text": "At the time of the writing of this article, there are two CAR T cells available, Kymriah, produced by Novrtis with a price tag of US$475,000 and Yescarta produced by Gilead Pharmaceuticals with a price tag of US$373,000, neither price including the required hospital admission in order to administer the agent in addition to potential treatment of side effects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29764166", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30145372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30233375", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27481247"
      ], 
      "type": "factoid", 
      "id": "5cb0856decadf2e73f000058", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 218, 
          "text": "The flavoenzyme dihydroorotate dehydrogenase (DHODH) catalyzes the fourth reaction of the de novo pyrimidine biosynthetic pathway, which exerts vital functions in the cells, especially within DNA and RNA biosynthesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Human dihydroorotate dehydrogenase (HsDHODH) is a key enzyme of pyrimidine de novo biosynthesis pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30233375", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "Dihydroorotate dehydrogenase (DHODH) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27481247", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List targets of classical analgesics.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19474215"
      ], 
      "type": "list", 
      "id": "5c9d18f1ecadf2e73f000033", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "Patient phenotypes in pharmacological pain treatment varies between individuals, which could be partly assigned to their genotypes regarding the targets of classical analgesics (OPRM1, PTGS2) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 184, 
          "offsetInEndSection": 339, 
          "text": "Morphine is the current gold standard analgesic acting at MOP receptors but produces a range of variably troublesome side-effects, in particular tolerance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19474215", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the effect of NFIA on astrocyte differentiation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
      ], 
      "type": "factoid", 
      "id": "5c8fe1f10101eac87000000a", 
      "snippets": [
        {
          "offsetInBeginSection": 647, 
          "offsetInEndSection": 857, 
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mode of action for Tocilizumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24729685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27790001"
      ], 
      "type": "summary", 
      "id": "5c960afaecadf2e73f00001e", 
      "snippets": [
        {
          "offsetInBeginSection": 498, 
          "offsetInEndSection": 800, 
          "text": "Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody against the IL-6 receptor and has been approved in many countries, including the United States, for the treatment of moderate to severe RA in patients who have not adequately responded to one or more disease-modifying antirheumatic drugs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 714, 
          "offsetInEndSection": 867, 
          "text": "Several clinical studies have demonstrated that a humanized anti-IL-6 receptor antibody, tocilizumab, improves clinical symptoms in rheumatoid arthritis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27790001", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the protein protamine 2 expressed?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28748416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28666211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26801756", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25516990", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24869677"
      ], 
      "type": "factoid", 
      "id": "5c9e6407ecadf2e73f000034", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 259, 
          "text": "This work aimed at investigating the effect of resveratrol on (1) DNA integrity and (2) fertilizing capacity of sperm by quantifying the presence of key paternal transcripts considered as markers for male fertility (protamine 1 [PRM1] and protamine 2 [PRM2]) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748416", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1186, 
          "offsetInEndSection": 1323, 
          "text": "biomarkers associated with spermatogenesis, including azoospermia-like (DAZL), phosphoglycerate kinase 2 (PGK2), and protamine 2 (PRM2). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28666211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 97, 
          "text": " Protamines are sperm nuclear proteins with a crucial role in chromatin condensation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26801756", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 481, 
          "offsetInEndSection": 570, 
          "text": "Expression of germ cell-specific proteins such as POU5F1, DAZL, TNP1, TNP2, PRM1 and PRM2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516990", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Human sperm express two types of protamine: protamine 1 (P1) and the family of protamine 2 (P2) proteins,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869677", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can miR-122 target RUNX2?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30070328"
      ], 
      "type": "yesno", 
      "id": "5c8fea130101eac87000000d", 
      "snippets": [
        {
          "offsetInBeginSection": 1373, 
          "offsetInEndSection": 1511, 
          "text": "MiR-122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting RUNX2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30070328", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Tocilizumab is an anti-TNF antibody, yes or no?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28401573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29495891"
      ], 
      "type": "yesno", 
      "id": "5c960d88ecadf2e73f00001f", 
      "snippets": [
        {
          "offsetInBeginSection": 595, 
          "offsetInEndSection": 676, 
          "text": "was treated with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28401573", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 658, 
          "text": "Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6\u00a0receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations. RA management guidelines and recommendations consider TCZ as one of the bDMARDS indicated after methotrexate or other conventional synthetic DMARDs and/or TNF inhibitors failure in adult RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29495891", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is it possible to analyze exosomes with FACS?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29783743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30290833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26154623"
      ], 
      "type": "yesno", 
      "id": "5c9e6ab9ecadf2e73f000035", 
      "snippets": [
        {
          "offsetInBeginSection": 1458, 
          "offsetInEndSection": 1516, 
          "text": "whose presence was validated by a bead-exosome FACS assay.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26154623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 467, 
          "text": "We analyzed exosomes from mouse (C57Bl/6) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including nanoparticle tracking analysis, biolayer interferometry, FACS, and electron microscopy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598503", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 749, 
          "offsetInEndSection": 924, 
          "text": "we applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct FACS analysis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 442, 
          "offsetInEndSection": 594, 
          "text": "we used a novel strategy for generating metabolically-labeled fluorescent exosomes that can be counted by flow cytometry assay (FACS) and characterized.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29783743", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which company developed opdivo?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30293207"
      ], 
      "type": "factoid", 
      "id": "5c910ae0ecadf2e73f000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 297, 
          "text": "As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb) of nivolumab (Opdivo\u00ae) to submit evidence of its clinical and cost effectiveness for metastatic or unresectable urothelial cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30293207", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are DMARDs?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27538766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27604908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28324149"
      ], 
      "type": "factoid", 
      "id": "5c960f21ecadf2e73f000020", 
      "snippets": [
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 179, 
          "text": "To determine the utility of ultrasonography in guiding modification of disease-modifying anti-rheumatic drug (DMARD) and steroid therapy for inflammatory arthritis (IA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27538766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 216, 
          "offsetInEndSection": 262, 
          "text": "disease-modifying antirheumatic drugs (DMARDs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1290, 
          "offsetInEndSection": 1352, 
          "text": "Treatment with disease-modifying antirheumatic drugs (DMARDs) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28324149", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the aim of the MitoCeption protocol?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28287607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25766410"
      ], 
      "type": "factoid", 
      "id": "5c9e6e99ecadf2e73f000036", 
      "snippets": [
        {
          "offsetInBeginSection": 782, 
          "offsetInEndSection": 1000, 
          "text": " The MitoCeption protocol described here allows the transfer of the mitochondria isolated beforehand from the donor cells to the target cells, using MSC mitochondria and glioblastoma stem cells (GSC) as a model system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28287607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 474, 
          "offsetInEndSection": 618, 
          "text": "We designed a protocol (MitoCeption) to directly and quantitatively transfer mitochondria, isolated from cell type A, to recipient cell type B. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766410", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can prevnar 13 be used in children?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22045904"
      ], 
      "type": "yesno", 
      "id": "5c915e51ecadf2e73f00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 721, 
          "offsetInEndSection": 1062, 
          "text": "PCV13 is approved for routine vaccination of all infants as a 4-dose series at age 2, 4, 6, and 12-15 months for children who previously received 1 or more doses of the 7-valent pneumococcal conjugate vaccine (PCV7), and for children with underlying medical conditions that increase their risk for pneumococcal disease or its complications. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1299, 
          "offsetInEndSection": 1580, 
          "text": "Based on published immunogenicity and safety data, as well as the recent recommendations by the ACIP for routine use in infants and indications for high-risk pediatric patients, PCV13 is a revised formulation of pneumococcal vaccine that should be included on pharmacy formularies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 148, 
          "text": "To review the immunogenicity, efficacy, and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) for use in pediatric patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List 3 indications for rituximab.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29606668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30358861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28185174", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28633733"
      ], 
      "type": "list", 
      "id": "5c961281ecadf2e73f000021", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 272, 
          "text": "o assess clinical outcomes including imaging findings on computed tomography (CT), pulmonary function testing (PFT), and glucocorticoid (GC) use in patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) treated with rituximab (RTX).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1805, 
          "offsetInEndSection": 1892, 
          "text": " RIX is the preferred off-label biologic drug for poly- and dermatomyositis in Germany.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 141, 
          "text": "Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not licensed for this indication", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30358861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 24, 
          "offsetInEndSection": 98, 
          "text": " rituximab in children and young people with juvenile idiopathic arthritis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30358861", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 79, 
          "offsetInEndSection": 285, 
          "text": "chronic lymphocytic leukemia (CLL) patients, including the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, phosphatidylinositol-3-kinase (PI3K) delta isoform inhibitor idelalisib combined with rituximab", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185174", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 349, 
          "text": "rituximab's efficacy has been well-documented in adults with refractory PF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633733", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 59, 
          "text": "Rituximab in the management of juvenile pemphigus foliaceus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633733", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Can mitochondria transfer from cell to cell?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29158129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29357914"
      ], 
      "type": "yesno", 
      "id": "5c9e738decadf2e73f000037", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Interest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29158129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2055, 
          "offsetInEndSection": 2160, 
          "text": "We show evidence that mitochondria transfer from Jurkat cells to MSCs, which is mediated by cell adhesion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1589, 
          "offsetInEndSection": 1721, 
          "text": "This process of mitochondria transfer is mediated by tunneling nanotubes, which are protrusions that extend from the cell membrane .", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357914", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Was stelara developed by Amgen?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28976302"
      ], 
      "type": "yesno", 
      "id": "5c9160bcecadf2e73f00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 264, 
          "offsetInEndSection": 484, 
          "text": "NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA\u00ae, Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976302", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List off label uses for Rituximab.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29797711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28742259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29574922", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30185361"
      ], 
      "type": "list", 
      "id": "5c961603ecadf2e73f000022", 
      "snippets": [
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 491, 
          "text": "Analysis of the data of the GRAID-2 registry for poly- and dermatomyositis.RESULTS: In 22\u00a0of the 23\u00a0patients in the GRAID-2 registry, rituximab (RIX) was administered, while 1\u00a0patient was given tocilizumab as off-label therapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 77, 
          "text": "Off-label use of rituximab to treat MS patients in Sweden is high", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29797711", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28742259", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 17, 
          "offsetInEndSection": 376, 
          "text": "immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long-term use (eg, corticosteroids) and overuse of off-label therapies (eg, rituximab) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29574922", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 288, 
          "text": "Conventional treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN) is associated with damage accrual, hence increased morbidity rate. Off-label use of rituximab (RTX) has shown significant promise in this patient group; however, data are still controversial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Outcomes of rituximab therapy in refractory lupus: A meta-analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185361", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Can mitochondria pass through membrane nanotubes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29335691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29362447"
      ], 
      "type": "yesno", 
      "id": "5c9e766becadf2e73f000038", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 279, 
          "text": "Membrane nanotubes (MNTs) act as \"highways\" between cells to facilitate the transfer of multiple signals and play an important role in many diseases. Our previous work reported on the transfer of mitochondria via MNTs between cardiomyocytes (CMs) and cardiac myofibroblasts (MFs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29362447", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Membrane nanotubes play important functional roles in numerous cell activities such as cellular transport and communication.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29335691", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Do tumour-associated macrophages have a prognostic role in gliomas?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28767130"
      ], 
      "type": "yesno", 
      "id": "5c92159becadf2e73f000012", 
      "snippets": [
        {
          "offsetInBeginSection": 67, 
          "offsetInEndSection": 340, 
          "text": "Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1659, 
          "offsetInEndSection": 1932, 
          "text": "This is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs. Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 941, 
          "offsetInEndSection": 1330, 
          "text": "Our data revealed that the amount of especially CD204+ TAMs increases with malignancy grade. In grade III-IV, high CD204 expression was associated with shorter survival, while high IBA-1 intensity correlated with a longer survival. In grade IV, CD204 showed independent prognostic value when adjusting for clinical data and the methylation status of O6-methylguanine-DNA methyltransferase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is Quorum Sensing in bacteria?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29130162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29130160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29095463"
      ], 
      "type": "summary", 
      "id": "5c978924ecadf2e73f000023", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 174, 
          "text": "Many Proteobacteria synthesize acyl-homoserine lactone (AHL) molecules for use as signals in cell density-dependent gene regulation known as quorum sensing (QS) and response.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 197, 
          "text": "In most bacteria, a global level of regulation, termed quorum sensing (QS), exists involving intercellular communication via the production and response to cell density-dependent signal molecules. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 358, 
          "offsetInEndSection": 596, 
          "text": " In many pathogenic microorganisms, communication systems, collectively termed quorum sensing (QS), have been observed to control a number of bacterial behaviours including expression of virulence factors and the development of biofilms. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29095463", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the cause of Krabbe disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28598007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29316812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29391017"
      ], 
      "type": "factoid", 
      "id": "5c9efde8ecadf2e73f000039", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Krabbe disease (KD) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28598007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Globoid cell leukodystrophy (GLD), or Krabbe disease, is an inherited, neurologic disorder that results from deficiency of a lysosomal enzyme, galactosylceramidase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29316812", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 118, 
          "text": "Krabbe disease is a rare neurodegenerative genetic disorder caused by deficiency of galactocerebrosidase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29391017", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Name a CFL2 mutation which is associated with nemaline myopathy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22560515"
      ], 
      "type": "factoid", 
      "id": "5c89623bf9c2ba6b28000004", 
      "snippets": [
        {
          "offsetInBeginSection": 469, 
          "offsetInEndSection": 703, 
          "text": "Because a mutation in CFL2 was identified in a family with nemaline myopathy, we performed sequence analysis of the gene and a novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met) of CFL2 was identified in both siblings. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560515", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What cellular process is the gene product of NANOG involved in?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28866747", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29177763", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29243835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29204746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29414604"
      ], 
      "type": "factoid", 
      "id": "5c9789a9ecadf2e73f000024", 
      "snippets": [
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 187, 
          "text": "The objective of this study was to explore the prognostic value of cancer stem cell markers, namely CD133, NANOG, and NOTCH1, in early stage oral squamous cell carcinoma (OSCC)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28866747", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 320, 
          "offsetInEndSection": 378, 
          "text": " transcription factors (TFs) such as Oct4, Sox2, and Nanog", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29177763", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 569, 
          "offsetInEndSection": 636, 
          "text": "expression of breast CSCs markers (CD44, ALDH1A1, Nanog, and Oct4),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29243835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1266, 
          "offsetInEndSection": 1310, 
          "text": "pluripotency markers OCT-4, SOX-2 and NANOG ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29204746", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 232, 
          "offsetInEndSection": 377, 
          "text": "The obtained induced pluripotent stem cell (iPSC) line showed pluripotency verified by the expression of pluripotency markers, NANOG, SOX2, OCT4,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29414604", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is TNF-\u03b1 an activator of pancreatic stellate cells?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24089530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20689058"
      ], 
      "type": "yesno", 
      "id": "5c9f0dabecadf2e73f00003b", 
      "snippets": [
        {
          "offsetInBeginSection": 825, 
          "offsetInEndSection": 910, 
          "text": "TNF-\u03b1 is the prime factor responsible for the activation of pancreatic stellate cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24089530", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 602, 
          "offsetInEndSection": 735, 
          "text": "Activated PSCs expressed IL-33 in the nucleus, and the expression was increased by IL-1\u03b2, TNF-\u03b1, PDGF-BB, and IFN-\u03b3, but not TGF-\u03b21. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689058", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Name the uses of Sideritis scardica in traditional medicine.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24487281"
      ], 
      "type": "list", 
      "id": "5c890ff475a4a5d219000010", 
      "snippets": [
        {
          "offsetInBeginSection": 106, 
          "offsetInEndSection": 396, 
          "text": "It is used in traditional medicine as a loosening agent in bronchitis and bronchial asthma; against the common cold and lung emphysema; in the treatment of inflammation, gastrointestinal disorders and coughs; and as an active constituent of dietary supplements for the prevention of anemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24487281", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1413, 
          "offsetInEndSection": 1777, 
          "text": "A broad range of activities of plant extracts and fractions as antimicrobial, anti-inflammatory, cytotoxic, antioxidant, gastroprotective, antiglioma, and triple monoamine reuptake inhibition as well as cultivation of the species as an approach for conservation of the natural habitats and provision of herb with high and permanent quality has also been presented.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24487281", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the phenotypic features of the autosomal dominant, development disease, Noonans syndrome", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28144274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29084544"
      ], 
      "type": "summary", 
      "id": "5c978a2aecadf2e73f000025", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 322, 
          "text": "Noonan syndrome (NS) is an autosomal dominant disorder with vast heterogeneity in clinical and genetic features. Various symptoms have been reported for this abnormality such as short stature, unusual facial characteristics, congenital heart abnormalities, developmental complications, and an elevated tumor incidence rate", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28144274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 605, 
          "text": "Noonan syndrome (NS) and Noonan syndrome with multiple lentigines (NSML) are autosomal dominant developmental disorders. NS and NSML are caused by abnormalities in genes that encode proteins related to the RAS-MAPK pathway, including PTPN11, RAF1, BRAF, and MAP2K. In this study, we diagnosed ten NS or NSML patients via targeted sequencing or whole exome sequencing (TS/WES).METHODS: TS/WES was performed to identify mutations in ten Chinese patients who exhibited the following manifestations: potential facial dysmorphisms, short stature, congenital heart defects, and developmental delay. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29084544", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are protamines ubiquitously expressed?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29797354"
      ], 
      "type": "yesno", 
      "id": "5c9f1b0cecadf2e73f00003c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Protamines are nuclear proteins which are specifically expressed in haploid male germ cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29797354", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are Crocus sativus compounds being considered against Alzheimer's disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28471166"
      ], 
      "type": "yesno", 
      "id": "5c891d5075a4a5d219000011", 
      "snippets": [
        {
          "offsetInBeginSection": 169, 
          "offsetInEndSection": 439, 
          "text": "Previous evidence suggested that Crocus sativus is linked to improving cognitive function in Alzheimer's disease (AD) patients. The aim of this study was to in vitro and in vivo investigate the mechanism(s) by which Crocus sativus exerts its positive effect against AD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1551, 
          "offsetInEndSection": 1690, 
          "text": "Collectively, findings from this study support the positive effect of Crocus sativus against AD by reducing A\u03b2 pathological manifestations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Rickettsia felis was described as a human pathogen almost two decades ago, what is it's main arthropod vector?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29079185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29217417"
      ], 
      "type": "factoid", 
      "id": "5c9791d2ecadf2e73f000026", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Cat fleas (Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29217417", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 231, 
          "offsetInEndSection": 358, 
          "text": " Morphological examination of 174 fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides felis).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29217417", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26697860", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29607687"
      ], 
      "type": "yesno", 
      "id": "5ca0848aecadf2e73f000044", 
      "snippets": [
        {
          "offsetInBeginSection": 873, 
          "offsetInEndSection": 1222, 
          "text": "Treatment with memantine, a noncompetitive NMDA receptor antagonist which is an approved drug for treatment of Alzheimer's disease, rescued protein phosphatase-2A activity by decreasing its demethylation at Leu309 selectively and attenuated Alzheimer's disease-like pathology and cognitive impairment in adeno-associated virus vector-1-I1PP2A rats. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26697860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 598, 
          "offsetInEndSection": 626, 
          "text": "anti-Amyloid agents (13.30%)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29607687", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 314, 
          "text": "no new drugs have been approved during the past 15\u00a0years; and the available medications are not cost-effective. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29607687", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Do Crocus sativus extracts loosen the blood-brain barrier?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28471166"
      ], 
      "type": "yesno", 
      "id": "5c891e5575a4a5d219000012", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid \u03b2 Load and Related Toxicity in 5XFAD Mice.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 523, 
          "offsetInEndSection": 1120, 
          "text": "In vitro results showed that Crocus sativus extract increases the tightness of a cell-based blood-brain barrier (BBB) model and enhances transport of A\u03b2. Further in vivo studies confirmed the effect of Crocus sativus extract (50 mg/kg/day, added to mice diet) on the BBB tightness and function that was associated with reduced A\u03b2 load and related pathological changes in 5XFAD mice used as an AD model. Reduced A\u03b2 load could be explained, at least in part, by Crocus sativus extract effect to enhance A\u03b2 clearance pathways including BBB clearance, enzymatic degradation and ApoE clearance pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of Acyl-Homoserine Lactone  in bacteria?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30352386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29130184"
      ], 
      "type": "summary", 
      "id": "5c979383ecadf2e73f000027", 
      "snippets": [
        {
          "offsetInBeginSection": 173, 
          "offsetInEndSection": 261, 
          "text": "tructural analogues of acyl homoserine lactones with Quorum Sensing antagonist activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30352386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "A number of bacteria use a class of chemical compounds called acyl-homoserine lactones (AHLs) as quorum sensing (QS) signals to coordinate their behavior at the population level", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130184", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are artificial blood cells available?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20234994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28406466"
      ], 
      "type": "yesno", 
      "id": "5ca0fa96ecadf2e73f000048", 
      "snippets": [
        {
          "offsetInBeginSection": 1638, 
          "offsetInEndSection": 1745, 
          "text": "The critical point for the break through for artificial blood products did not come yet but could be ahead-", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20234994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "We suggest a novel method that uses artificial blood cells (hemoglobin vesicles, Hb-Vs) as photosensitizers in dye laser treatment (at 595-nm wavelength) for port-wine stains (i.e., capillary malformations presenting as red birthmarks) based on the results of animal experiments. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406466", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Have apolipoprotein mimetics been used in clinical trials?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25157031"
      ], 
      "type": "yesno", 
      "id": "5c895cf0f9c2ba6b28000001", 
      "snippets": [
        {
          "offsetInBeginSection": 1230, 
          "offsetInEndSection": 1329, 
          "text": "One of these (AEM-28) has recently been given orphan drug status and is undergoing clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25157031", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are 2 organisms that can cause Human toxocariasis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29733009"
      ], 
      "type": "list", 
      "id": "5c979ffcecadf2e73f000028", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Human toxocariasis, a worldwide parasitic disease, is caused by the larval stage of intestinal nematodes of dogs and cats, namely Toxocara canis and Toxocara cati", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29733009", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is actin present in the nucleus?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29568381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29925947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30019087", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30312531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30193156"
      ], 
      "type": "yesno", 
      "id": "5ca0fdb0ecadf2e73f000049", 
      "snippets": [
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 812, 
          "text": "Moreover, inhibition of ATM kinase or deficiency in nuclear actin polymerization causes carcinogenic RET/PTC chromosome rearrangements after DSBs induction in human cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1024, 
          "offsetInEndSection": 1209, 
          "text": " Our findings establish that nuclear actin-based mobility shapes chromatin organization by generating repair domains that are essential for homology-directed repair in eukaryotic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29925947", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 579, 
          "offsetInEndSection": 751, 
          "text": "The discovery of nuclear actin opened new perspective on the field, suggesting that the nuclear activities of actin reflect the functions of primordial actin-like proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30019087", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 114, 
          "offsetInEndSection": 282, 
          "text": " The revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30312531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "While it is long known that actin is part of the nuclear proteome, its properties and functions as regulated, functional and dynamically assembled actin filaments are only recently emerging.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30193156", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the dbSUPER database?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26438538"
      ], 
      "type": "summary", 
      "id": "5c8960a6f9c2ba6b28000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 65, 
          "text": "dbSUPER: a database of super-enhancers in mouse and human genome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 565, 
          "offsetInEndSection": 1460, 
          "text": "We developed dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease. dbSUPER provides a responsive and user-friendly web interface to facilitate efficient and comprehensive search and browsing. The data can be easily sent to Galaxy instances, GREAT and Cistrome web-servers for downstream analysis, and can also be visualized in the UCSC genome browser where custom tracks can be added automatically. The data can be downloaded and exported in variety of formats. Furthermore, dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez. dbSUPER also provides an overlap analysis tool to annotate user-defined regions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List places in the body where somatostatin is produced.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25777539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24627166", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23894587", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23370538", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19819962"
      ], 
      "type": "list", 
      "id": "5c97f579ecadf2e73f00002a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Somatostatin (SST) is a neuromodulator which is abundant throughout the central nervous system (CNS)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25777539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Somatostatin (SST) is abundantly produced by the human retina, and the main source is the retinal pigment epithelium (RPE).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627166", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Somatostatin (Som), one of the most concentrated neuropeptides in the brain, is highly expressed in the olfactory bulb (OB)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894587", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "The production of somatostatin interneurons in the olfactory bulb is regulated by the transcription factor sp8", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894587", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Somatostatin expression in human hair follicles and its potential role in immune privilege", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23370538", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "The kinetics of insulin, glucagon and somatostatin release was studied in human pancreatic islets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819962", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819962", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is the Philadelphia chromosome a fusion between parts of chromosomes 1 and 9?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29046997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29435292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29633730"
      ], 
      "type": "yesno", 
      "id": "5ca10fefecadf2e73f00004a", 
      "snippets": [
        {
          "offsetInBeginSection": 192, 
          "offsetInEndSection": 388, 
          "text": " The Philadelphia chromosome, t(9;22)(q34;q11), is present in 95% of CML patients, resulting in constitutive tyrosine kinase activity; however, ~5% of CML patients possess a Philadelphia variant. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29435292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Chronic Myeloid Leukemia (CML) is myeloproliferative neoplasm characterized by Philadelphia chromosome which is a balanced translocation between chromosome 9 and 22 in 90% of cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29633730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Chronic myeloid leukemia is a stem cell disease with the presence of Philadelphia chromosome generated through reciprocal translocation of chromosome 9 and 22. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046997", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is YESCARTA?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29501911"
      ], 
      "type": "summary", 
      "id": "5c896ce0d558e5f232000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 442, 
          "text": "Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah\u2122 and Yescarta\u2122) were recently approved by the FDA. Kymriah\u2122 is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta\u2122 is for the treatment of adult patients with R/R large B cell lymphoma. In common, both are CD19-specific CAR T cell therapies lysing CD19-positive targets. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29501911", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the 3 types of immunoglobulin heavy chain containing antibodies found in human breast milk?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28586632"
      ], 
      "type": "list", 
      "id": "5c9f79c3ecadf2e73f00003d", 
      "snippets": [
        {
          "offsetInBeginSection": 590, 
          "offsetInEndSection": 887, 
          "text": "This is a descriptive cross-sectional study of a convenience sample of 67 donated colostrum samples at different days after delivery, both raw and pasteurized. Antibody profiles were analyzed at different times during breastfeeding, and total and specific antibodies (IgM, IgA, and IgG subclasses)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28586632", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a exposome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28836271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28494612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29169635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29676625"
      ], 
      "type": "factoid", 
      "id": "5cb0d647ecadf2e73f000059", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "The interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28836271", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 897, 
          "offsetInEndSection": 1109, 
          "text": "The high-throughput and holistic approaches to biomarker discovery used extensively in large-scale molecular epidemiological exposome are also discussed in the context of human exposure to environmental stressors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28494612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 499, 
          "offsetInEndSection": 679, 
          "text": "Experimental data strongly suggests a complex interaction between the exposome (or environmental influences) and genome (genetic material) to produce epigenetic changes (epigenome)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169635", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1095, 
          "offsetInEndSection": 1307, 
          "text": "Exposome factors including nutrition, medication, occupational factors, pollutants, climatic factors, and psychosocial and lifestyle factors may impact on the course and severity of acne and on treatment efficacy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29377341", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 425, 
          "offsetInEndSection": 708, 
          "text": " The exposome is a novel conceptual framework that allows for concurrent examination of multiple intrinsic and extrinsic factors, including environmental exposures, as well as changes in exposures over time, to elucidate the complex environmental factors that affect health outcomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29676625", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What does the strimvelis treatment consist of?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29625577"
      ], 
      "type": "factoid", 
      "id": "5c897167d558e5f232000005", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 342, 
          "text": "Strimvelis (autologous CD34+ cells transduced to express adenosine deaminase [ADA]) is the first ex vivo stem cell gene therapy approved by the European Medicines Agency (EMA), indicated as a single treatment for patients with ADA-severe combined immunodeficiency (ADA-SCID) who lack a suitable matched related bone marrow donor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625577", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can therapeutic levels of  Vedolizumab be found in the breast milk of nursing mothers following treatment for Inflammatory bowel disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28961712"
      ], 
      "type": "yesno", 
      "id": "5c9f7bb6ecadf2e73f00003e", 
      "snippets": [
        {
          "offsetInBeginSection": 1086, 
          "offsetInEndSection": 1351, 
          "text": "Vedolizumab can be detected in the breast milk of nursing mothers. Although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro-intestinal immune-suppression of the infant.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961712", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is predicted using SURFY?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30373828"
      ], 
      "type": "factoid", 
      "id": "5cb0e4a6ecadf2e73f00005b", 
      "snippets": [
        {
          "offsetInBeginSection": 412, 
          "offsetInEndSection": 526, 
          "text": "o enable analysis of the human surfaceome, we developed the surfaceome predictor SURFY, based on machine learning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30373828", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which was the first adeno-associated virus vector gene therapy product approved in the United States?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30089698"
      ], 
      "type": "factoid", 
      "id": "5c897555d558e5f232000009", 
      "snippets": [
        {
          "offsetInBeginSection": 1755, 
          "offsetInEndSection": 2009, 
          "text": "Gene therapy utilizing viral vectors has experienced recent success, culminating in U.S. Food and Drug Administration approval of the first adeno-associated virus vector gene therapy product in the United States: Luxturna for inherited retinal dystrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30089698", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is aphasia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26999324", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28691196"
      ], 
      "type": "summary", 
      "id": "5c9fb2aaecadf2e73f00003f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Aphasia, the language disorder following brain damage, is frequently accompanied by deficits of working memor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999324", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 82, 
          "text": "People with aphasia (PWA) use pantomime, gesture in absence of speech,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691196", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is known about the gene MIR140?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21576357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24973690", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28928081"
      ], 
      "type": "summary", 
      "id": "5c8a8f56d558e5f23200000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576357", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1228, 
          "offsetInEndSection": 1456, 
          "text": "These results demonstrate that Mir140 is essential for normal endochondral bone development and suggest that the reduced BMP signaling caused by Dnpep upregulation plays a causal role in the skeletal defects of Mir140-null mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576357", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 831, 
          "offsetInEndSection": 902, 
          "text": "Transcripts associated with cartilage development (e.g., Acan, miR140) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24973690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1703, 
          "offsetInEndSection": 1977, 
          "text": "Our findings showed the novel transcriptional role of miR140-5p in the expression of Nrf2 and miR-140-5p protected against Cisplatin induced oxidative stress by activating Nrf2-dependent antioxidant pathway, providing a potentially therapeutic target in acute kidney injury.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928081", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene therapy treatment is FDA approved for retinal dystrophy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30089698"
      ], 
      "type": "factoid", 
      "id": "5c89773ed558e5f23200000a", 
      "snippets": [
        {
          "offsetInBeginSection": 1755, 
          "offsetInEndSection": 2010, 
          "text": "Gene therapy utilizing viral vectors has experienced recent success, culminating in U.S. Food and Drug Administration approval of the first adeno-associated virus vector gene therapy product in the United States: Luxturna for inherited retinal dystrophy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30089698", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Salivary Cortisol is a biomarker for what disease/syndrome/condition?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23971022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29455296", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30408721"
      ], 
      "type": "factoid", 
      "id": "5c9fb428ecadf2e73f000041", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30408721", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 55, 
          "offsetInEndSection": 84, 
          "text": "ortisol as a stress biomarker", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29455296", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 267, 
          "text": "The salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971022", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the cGAS pathway?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29169058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30395807", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28137885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28801534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28920955", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28940468", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27648547", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26944200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27902332"
      ], 
      "type": "factoid", 
      "id": "5c8aa082d558e5f23200000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Cyclic di-AMP (c-di-AMP) is a bacterial signaling nucleotide synthesized by several human pathogens.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169058", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 296, 
          "text": "Cyclic GMP-AMP synthase (cGAS) has recently been identified as the primary protein that detects cytosolic double stranded DNA to invoke a type I interferon response. The cGAS pathway is vital in the recognition of DNA encoded viruses as well as self-DNA leaked from the nucleus of damaged cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30395807", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 887, 
          "offsetInEndSection": 1053, 
          "text": "These results indicate that activation of the cGAS pathway is important for intrinsic antitumor immunity and that cGAMP may be used directly for cancer immunotherapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28137885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 881, 
          "offsetInEndSection": 1019, 
          "text": " this work identifies long DNA as the molecular entity stimulating the cGAS pathway upon cytosolic DNA challenge such as viral infections.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28801534", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 872, 
          "offsetInEndSection": 1155, 
          "text": "these data suggest that inactivation of the cGAS pathway plays a critical role in tumour progression, and reveal a direct link between hypoxia-responsive miRNAs and adaptive immune responses to the hypoxic tumour microenvironment, thus unveiling potential new therapeutic strategies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28920955", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 306, 
          "text": "dysregulation of the cGAS pathway is linked to autoimmune diseases while targeted stimulation may be of benefit in immunoncology. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28940468", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 299, 
          "offsetInEndSection": 510, 
          "text": "The cGAS-STING pathway not only mediates protective immune defense against infection by a large variety of DNA-containing pathogens but also detects tumor-derived DNA and generates intrinsic antitumor immunity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648547", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 890, 
          "offsetInEndSection": 1052, 
          "text": "our data indicate that the cGAS-STING pathway plays a role in the surveillance of HBV infection and may be exploited for development of novel anti-HBV strategies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902332", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does RUNX2 inhibit astrocyte differentiation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27546532"
      ], 
      "type": "yesno", 
      "id": "5c8fe71b0101eac87000000b", 
      "snippets": [
        {
          "offsetInBeginSection": 610, 
          "offsetInEndSection": 886, 
          "text": "The method was able to recapitulate experimentally validated cell-fate determinants, and validation of two predicted cell-fate determinants confirmed that overexpression of ESR1 and RUNX2 in mouse neural stem cells induces neuronal and astrocyte differentiation, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27546532", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are 5 key questions in human performance modeling?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29531424"
      ], 
      "type": "list", 
      "id": "5c9fb583ecadf2e73f000042", 
      "snippets": [
        {
          "offsetInBeginSection": 254, 
          "offsetInEndSection": 667, 
          "text": "the five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29531424", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mode of action of the Tc toxins?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11286884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15679840", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23870259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24572368", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27571177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28233068", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30232455"
      ], 
      "type": "summary", 
      "id": "5c98fcf0ecadf2e73f00002c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 268, 
          "text": "Tc toxins secrete toxic enzymes into host cells using a unique syringe-like injection mechanism. They are composed of three subunits, TcA, TcB and TcC. TcA forms the translocation channel and the TcB-TcC heterodimer functions as a cocoon that shields the toxic enzyme.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30232455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "The toxin complex (tc) genes of Photorhabdus encode insecticidal, high molecular weight Tc toxins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11286884", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "The toxin complex (tc) genes of bacteria comprise a large and growing family whose mode of action remains obscure. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15679840", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Tc toxins are widely distributed among different gram-negative and gram-positive bacteria, where they act as pathogenicity factors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23870259", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 211, 
          "text": "Tripartite Tc toxin complexes of bacterial pathogens perforate the host membrane and translocate toxic enzymes into the host cell, including in humans. The underlying mechanism is complex but poorly understood. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24572368", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "Tc toxins from pathogenic bacteria use a special syringe-like mechanism to perforate the host cell membrane and inject a deadly enzyme into the host cytosol. The molecular mechanism of this unusual injection system is poorly understood.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27571177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Various bacterial toxins have potent insecticidal activity. Recently, the Toxin complexes (Tc's) of Photorhabdus and Xenorhabdus species have become an increased focus of current research.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28233068", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What does RUNX2 stand for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19121369"
      ], 
      "type": "factoid", 
      "id": "5c8fe7cb0101eac87000000c", 
      "snippets": [
        {
          "offsetInBeginSection": 367, 
          "offsetInEndSection": 396, 
          "text": "Runt related factor-2 (Runx2)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19121369", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29413774"
      ], 
      "type": "factoid", 
      "id": "5c9ff25eecadf2e73f000043", 
      "snippets": [
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 274, 
          "text": "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413774", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are cardenolides inhibitors of Na+/K+ ATPase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30053394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29683473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30372816"
      ], 
      "type": "yesno", 
      "id": "5c9906dcecadf2e73f00002f", 
      "snippets": [
        {
          "offsetInBeginSection": 257, 
          "offsetInEndSection": 493, 
          "text": ". Previously, we reported that a variety of cardenolides impart anti-transmissible gastroenteritis coronavirus (TGEV) activity in swine testicular (ST) cells, through targeting of the cell membrane sodium/potassium pump, Na+/K+-ATPase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 970, 
          "offsetInEndSection": 1092, 
          "text": ": We found evidence for low cardenolides by HPLC, but substantial toxicity when extracts were assayed on Na+ /K+ -ATPases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29683473", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 490, 
          "text": "Cardenolides have shown significant antitumor activity due to their ability to inhibit the Na+K+ATPase enzyme, and the expression of this enzyme is increased in tumor cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30372816", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can antisense threapy be used for Huntington's disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22726826"
      ], 
      "type": "yesno", 
      "id": "5c900779ecadf2e73f000001", 
      "snippets": [
        {
          "offsetInBeginSection": 89, 
          "offsetInEndSection": 290, 
          "text": "In this issue of Neuron, Kordasiewicz et\u00a0al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22726826", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "\"Huntingtin holiday\": progress toward an antisense therapy for Huntington's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22726826", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What are acoustic reported genes used to detect?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29300010"
      ], 
      "type": "summary", 
      "id": "5ca9f932ecadf2e73f000054", 
      "snippets": [
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 659, 
          "text": "acoustic reporter genes, which are genetic constructs that allow bacterial gene expression to be visualized in vivo using ultrasound,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29300010", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a lipin 1 protein doing?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29457836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30028636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30092116"
      ], 
      "type": "summary", 
      "id": "5ca3bfd7ecadf2e73f00004b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Lipin 1 regulates glycerolipid homeostasis by acting as a phosphatidic acid phosphohydrolase (PAP) enzyme in the triglyceride-synthesis pathway and by regulating transcription factor activity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 219, 
          "text": "As a lipin family founding member, lipin1 exerts dual functions as a phosphatidate phosphatase enzyme and/or a co-transcriptional regulator in lipid metabolism. In fact, it is also involved in many other cell processes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30092116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1381, 
          "offsetInEndSection": 1409, 
          "text": "lipogenic regulator lipin 1 ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which company produces patisiran?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30251172"
      ], 
      "type": "factoid", 
      "id": "5c900b9eecadf2e73f000004", 
      "snippets": [
        {
          "offsetInBeginSection": 426, 
          "offsetInEndSection": 722, 
          "text": "Patisiran has been developed by Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and subsequently approved in the EU for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30251172", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What protein is recruited by Crumbs to regulate tracheal development?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25065756", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21172808"
      ], 
      "type": "factoid", 
      "id": "5caa0247ecadf2e73f000055", 
      "snippets": [
        {
          "offsetInBeginSection": 1144, 
          "offsetInEndSection": 1320, 
          "text": "We propose that early endocytosis maintains normal steady-state levels of Crumbs, which recruits apical phosphorylated (active) Moe, which in turn regulates seamless tube shape", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25065756", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 717, 
          "offsetInEndSection": 962, 
          "text": "There, Crb, acting in parallel with the epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Moe).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21172808", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is collagen matrix of human articular cartilage changing with disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27384346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20488735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18991091"
      ], 
      "type": "yesno", 
      "id": "5ca5127eecadf2e73f00004c", 
      "snippets": [
        {
          "offsetInBeginSection": 943, 
          "offsetInEndSection": 1110, 
          "text": "The collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27384346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1055, 
          "offsetInEndSection": 1164, 
          "text": "the chondrocytes in ageing articular cartilage have limited capacity to turnover the interterritorial matrix.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18991091", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Type II collagen is a major component of articular cartilage and its breakdown is a key feature of osteoarthritis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20488735", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2155, 
          "offsetInEndSection": 2304, 
          "text": "The resultant composition of the cartilage suggests that the loss may primarily involve \"resident\" molecules originally present in healthy cartilage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9920023", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is ustekinumab a polyclonal antibody?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29164954"
      ], 
      "type": "yesno", 
      "id": "5c9162b5ecadf2e73f00000e", 
      "snippets": [
        {
          "offsetInBeginSection": 5, 
          "offsetInEndSection": 177, 
          "text": "Ustekinumab, a human monoclonal IgG1 antibody targeting the p40-subunit shared by interleukin (IL)12 and IL-23, represents a potential treatment for atopic dermatitis (AD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29164954", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where in the body, is ghrelin secreted?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29392854"
      ], 
      "type": "factoid", 
      "id": "5caa06d0ecadf2e73f000056", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 99, 
          "text": "Ghrelin, an orexigenic peptide, is secreted from endocrine cells in the gastric mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29392854", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List the ERM proteins.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29329782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29311472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29777033"
      ], 
      "type": "list", 
      "id": "5ca64b5becadf2e73f000051", 
      "snippets": [
        {
          "offsetInBeginSection": 423, 
          "offsetInEndSection": 458, 
          "text": "ezrin/radixin/moesin (ERM) proteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29329782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 491, 
          "offsetInEndSection": 531, 
          "text": "ezrin, radixin and moesin (ERM proteins)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29311472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 240, 
          "text": "Ezrin/radixin/moesin (ERM) proteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29777033", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is epitranscriptomics?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29671387"
      ], 
      "type": "summary", 
      "id": "5c922bc3ecadf2e73f000013", 
      "snippets": [
        {
          "offsetInBeginSection": 1047, 
          "offsetInEndSection": 1191, 
          "text": "Here we provide a perspective on necessary and expected developments in the fast expanding area of RNA modifications, termed epitranscriptomics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29671387", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is resistin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29278852"
      ], 
      "type": "factoid", 
      "id": "5c840782617e120c34000006", 
      "snippets": [
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 800, 
          "text": "Resistin, a pro-inflammatory cytokine, is predictive of atherosclerosis and poor clinical outcomes in patients with coronary artery disease and ischemic stroke", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278852", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 394, 
          "text": "Leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278852", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Pim-1 a protein phosphatase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29399171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29355758"
      ], 
      "type": "yesno", 
      "id": "5cb37f76ecadf2e73f00005c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Pim-1 proto-oncogene, serine/threonine kinase (PIM-1) phosphorylates a series of substrates to exert its oncogenic function in numerous malignancies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29399171", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 208, 
          "text": "The Pim1 serine/threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355758", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Name three binding partners of cofilin 2.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28886070", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19752190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25373779"
      ], 
      "type": "list", 
      "id": "5c9007460101eac870000012", 
      "snippets": [
        {
          "offsetInBeginSection": 459, 
          "offsetInEndSection": 642, 
          "text": "Cofilin-2 (Cfl2) was identified as one of the potential targets of miR-301a using prediction databases, which we validated by luciferase assay and mutation of predicted binding sites.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28886070", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Cofilin weakly interacts with 14-3-3 and therefore can only indirectly participate in regulation of cell motility by small heat shock protein HspB6 (Hsp20).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22450169", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 437, 
          "offsetInEndSection": 738, 
          "text": "In contrast to other isoforms, cofilin-2 efficiently binds and disassembles both ADP- and ATP/ADP-Pi-actin filaments. We mapped surface-exposed cofilin-2-specific residues required for ATP-actin binding and propose that these residues function as an \"actin nucleotide-state sensor\" among ADF/cofilins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373779", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of GvpA?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28898511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25648404"
      ], 
      "type": "factoid", 
      "id": "5ca9f846ecadf2e73f000053", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "Gas vesicles are proteinaceous, gas-filled nanostructures produced by some bacteria and archaea. The hydrophobic major structural protein GvpA forms the ribbed gas vesicle wall.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28898511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 801, 
          "offsetInEndSection": 898, 
          "text": " The gas vesicle wall is solely formed of proteins with the two major components, GvpA and GvpC, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648404", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the crystal structure of Pim-1 available?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30033129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25575657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22926267", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23936194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22339127", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16227208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15808862"
      ], 
      "type": "yesno", 
      "id": "5cb380b8ecadf2e73f00005d", 
      "snippets": [
        {
          "offsetInBeginSection": 505, 
          "offsetInEndSection": 673, 
          "text": "Recent crystallographic studies of Pim-1 have identified unique structural features but have not provided insight into how the kinase recognizes its target substrates. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16227208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 351, 
          "offsetInEndSection": 454, 
          "text": "a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30033129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 425, 
          "text": "The crystal structure of this compound with PIM1 confirmed the predicted binding mode and protein-ligand interactions except those in the acidic ribose pocket. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25575657", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 422, 
          "offsetInEndSection": 690, 
          "text": "Using the determined X-ray crystal structure of PIM1 complexed to the compound 1-R as a control, we discuss the importance of including the protein flexibility inherent in the ensemble docking protocol, for the accuracy of the structure prediction of the bound state. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926267", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 391, 
          "offsetInEndSection": 530, 
          "text": "Here, we describe the crystal structure of Pim1 in complex with a newly developed pyrido[4,3-d]pyrimidine-derivative inhibitor (SKI-O-068).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23936194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 211, 
          "text": "Crystallographic and docking data analyses have been undertaken using inhibitor complexes ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339127", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 378, 
          "offsetInEndSection": 459, 
          "text": "The crystal structures of Pim1 in apo form and bound with AMPPNP have been solved", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15808862", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the indication for KYMRIAH?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29501911"
      ], 
      "type": "factoid", 
      "id": "5c896f60d558e5f232000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 357, 
          "text": "Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah\u2122 and Yescarta\u2122) were recently approved by the FDA. Kymriah\u2122 is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta\u2122 is for the treatment of adult patients with R/R large B cell lymphoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29501911", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a SMR based BCI?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29075937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30063219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26891350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30414824"
      ], 
      "type": "summary", 
      "id": "5c521c8c7e3cb0e231000007", 
      "snippets": [
        {
          "offsetInBeginSection": 395, 
          "offsetInEndSection": 458, 
          "text": " sensorimotor rhythm-based brain-computer interfaces (SMR-BCI) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29075937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 209, 
          "offsetInEndSection": 403, 
          "text": "Here, we studied the immediate and therapeutic effects of BCI-based training to control pre-movement sensorimotor rhythm (SMR) amplitude on robot-assisted finger extension in people with stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30063219", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 404, 
          "offsetInEndSection": 482, 
          "text": " Especially for BCIs based on the modulation of the Sensorimotor Rhythm (SMR) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26891350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 5, 
          "offsetInEndSection": 119, 
          "text": "Brain Computer Interface (BCI) and neurofeedback studies have investigated the impact of sensorimotor rhythm (SMR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30414824", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is myc a tumour suppressor gene?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27532209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27880072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28430012", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28833404"
      ], 
      "type": "yesno", 
      "id": "5cb38a56ecadf2e73f00005e", 
      "snippets": [
        {
          "offsetInBeginSection": 255, 
          "offsetInEndSection": 374, 
          "text": "oncogenic Myc, a master transcription factor that turns on anabolic metabolism to promote cell growth in many cancers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 634, 
          "offsetInEndSection": 649, 
          "text": "he MYC oncogene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27880072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 653, 
          "offsetInEndSection": 686, 
          "text": " the proto-oncogene protein c-MYC", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430012", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 188, 
          "text": "however, other genes such as the proto-oncogene c-Myc are promising targets for anticancer therapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28833404", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which syndrome is associated to SAMHD1 gene mutations?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29583030"
      ], 
      "type": "factoid", 
      "id": "5c93e8bdecadf2e73f00001c", 
      "snippets": [
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 413, 
          "text": "Its emerging role as an effector of innate immunity is affirmed by mutations in the SAMHD1 gene that cause the severe autoimmune disease, Aicardi-Goutieres syndrome (AGS) and that are linked to cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29583030", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List proteins with RING domain.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29187402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29107100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29432170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29426838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29324855", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29471350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29295817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29320607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29367421"
      ], 
      "type": "list", 
      "id": "5c990afbecadf2e73f000030", 
      "snippets": [
        {
          "offsetInBeginSection": 512, 
          "offsetInEndSection": 581, 
          "text": " The RING domain of RING1 was required for its E3 Ub ligase activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 398, 
          "text": " The TRIM proteins are classically characterized by the presence of an amino-terminal RING domain and a B-box domain followed by a coiled coil domain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29107100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 217, 
          "offsetInEndSection": 311, 
          "text": "the detailed mechanism by which the TRAF6 RING dimer promotes ubiquitin transfer was unknown. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432170", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "RING ubiquitin E3 ligases enclose a RING domain for ubiquitin ligase activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29324855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 917, 
          "offsetInEndSection": 935, 
          "text": " UHRF1 RING domain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 282, 
          "offsetInEndSection": 336, 
          "text": " MARCH7, a RING domain-containing ubiquitin E3 ligase,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29295817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Seven in absentia (SINA) protein is one subgroup of ubiquitin ligases possessing an N-terminal cysteine-rich really interesting new gene (RING) domain,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29320607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 136, 
          "offsetInEndSection": 179, 
          "text": "The BRCA1 RING domain is a ubiquitin ligase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29367421", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What conditions are associated with mutations in the gene FAAH?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22442717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22912404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20098695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12060782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10764768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27327781"
      ], 
      "type": "summary", 
      "id": "5c9d170cecadf2e73f000032", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 225, 
          "text": "FAAH (fatty acid amide hydrolase), primarily expressed in the liver, hydrolyzes the endocannabinoids fatty acid ethanolamides (FAA). Human FAAH gene mutations are associated with increased body weight and obesity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442717", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 145, 
          "offsetInEndSection": 225, 
          "text": "Human FAAH gene mutations are associated with increased body weight and obesity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442717", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 98, 
          "offsetInEndSection": 161, 
          "text": "whereas mutations in FAAH are associated with obesity in humans", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22912404", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 907, 
          "offsetInEndSection": 1162, 
          "text": "Collectively, these results suggest that genetic mutations in FAAH may constitute important risk factors for problem drug use and support a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12060782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1817, 
          "offsetInEndSection": 2082, 
          "text": "This is the first study to document that FAAH 385 A mutant alleles have a direct effect on elevated plasma levels of anandamide and related NAEs in humans. These biomarkers may indicate risk for severe obesity and may suggest novel ECS obesity treatment strategies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20098695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1313, 
          "offsetInEndSection": 1769, 
          "text": "nerve growth factor (NGFB), its tyrosine kinase receptor (NTRK1) and the fatty acid amide hydrolase (FAAH) have become targets of interest. For most of these genes, functional variants have been associated with neuro-psychiatric disorders and not yet with analgesia. However, research on the genetic modulation of pain has already identified variants in these genes, relative to pain, which may facilitate the pharmacogenetic assessments of new analgesics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the results of mutations in the gene autoimmune regulator?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29150834", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29427825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29437776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29666621"
      ], 
      "type": "factoid", 
      "id": "5cb39707ecadf2e73f000060", 
      "snippets": [
        {
          "offsetInBeginSection": 296, 
          "offsetInEndSection": 456, 
          "text": "a rare inherited disorder called autoimmune polyendocriopathy candidiasis ectodermal dystrophy (APECED) caused by mutations in autoimmune regulator (AIRE) gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29150834", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 338, 
          "offsetInEndSection": 559, 
          "text": "The crucial role played by AIRE in central immune tolerance emerged in the studies on the pathogenesis of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy, a rare inherited polyendocrine/autoimmune disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29427825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 258, 
          "text": "Autoimmune polyendocrine syndrome type 1 (APS-1; OMIM #240300), also referred to as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare monogenic autoimmune disorder caused by mutations in the autoimmune regulator (AIRE) gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29437776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a primary immunodeficiency caused by mutations in the autoimmune regulator gene (AIRE)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29666621", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is CD63 an exosomal marker?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28346015", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28819811", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28770472"
      ], 
      "type": "yesno", 
      "id": "5cb3a2dd99d1e53537000001", 
      "snippets": [
        {
          "offsetInBeginSection": 701, 
          "offsetInEndSection": 746, 
          "text": "f exosome marker proteins (e.g., CD63, Alix) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28770472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 427, 
          "offsetInEndSection": 513, 
          "text": " CD63 levels and acetylcholinesterase (AChE) activity were used as markers of exosome,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28819811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 475, 
          "text": " The results demonstrated these exosomes all expressed CD9, CD63, CD81, Alix", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28346015", 
          "endSection": "abstract"
        }
      ]
    }
  ]
}